FIMECS, Inc.
- Biotech or pharma, therapeutic R&D
FIMECS, Inc. is a Japan-based biotech company advancing small-molecule drug discovery through our proprietary RaPPIDS™ platform for Targeted Protein Degradation (TPD). RaPPIDS™ integrates rapid synthesis and phenotypic screening to generate potent degraders, even for undruggable targets.
We are currently seeking new research collaborations with pharmaceutical partners to apply RaPPIDS™ to novel targets. In parallel, we are actively looking for the opportunities to out-license our lead preclinical asset, FIM-001—a first-in-class IRAK-M degrader for cancer immunotherapy. FIM-001 is IND-ready and has demonstrated strong in vivo efficacy and immune activation in immune checkpoint inhibitor-resistant tumor models.
We invite discussions with partners interested in TPD innovation, collaborative research opportunities, or exclusive licensing of FIM-001.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}